Indication Type	Indication	Approval Level	Dose Form
Treatment of	Corneal erosions	••••••••••••	•••••••• • •••••
Treatment of	Herpes simplex virus keratitis	••••••••••••	•••••••• • •••••
Treatment of	Keratitis viral	••••••••••••	•••••••• • •••••

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

In chemical structure idoxuridine closely approximates the configuration of thymidine, one of the four building blocks of DNA (the genetic material of the Herpes virus). As a result, idoxuridine is able to replace thymidine in the enzymatic step of viral replication or "growth". The consequent production of faulty DNA results in a pseudostructure which cannot infect or destroy tissue. In short, by pre-empting a vital building block in the genetic material of the Herpes simplex virus, Herplex-D topical solution destroys the infective and destructive capacity of the viral material. The virus infected cell may only be attacked during the period of active synthesis of DNA. This occurs early in the development of the Herpes simplex lesion, but at different times in different cells. Therefore, ideally, the affected area should remain saturated with the antiviral agent.

Mechanism of action

Idoxuridine acts as an antiviral agent by inhibiting viral replication by substituting itself for thymidine in viral DNA. This in turn inhibits thymidylate phosphorylase and viral DNA polymerases from properly functioning. The effect of Idoxuridine results in the inability of the virus to reproduce or to infect/destroy tissue.

Target	Actions	Organism
ADNA	other	Humans
UThymidine kinase	unknown	HHV-1

Absorption

Systemic absorption is unlikely following ocular administration even when nasolacrimal secretions are swallowed, since vidarabine is rapidly deaminated in the gastrointestinal tract.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Idoxuridine is rapidly inactivated by deaminases or nucleotidases.

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Hypersensitivity or increased sensitivity of eyes to light. LD₅₀=3080 mg/kg (orally in mice).

Pathways

Not Available

Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">: This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions: No interactions found.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

International/Other Brands

Herpid (Astellas) / Herpidu (Ciba Vision) / Idulea (Elea) / Idustatin (Sanofi) / Keresid (GlaxoSmithKline) / Oftan IDU (Santen) / Virexen (Viñas)

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Dendrid	Solution / drops	1 mg/1mL	Ophthalmic	ALCON LABORATORIES, INC.	1963-06-28	1995-12-31
Herplex	Solution / drops	.1 %	Ophthalmic	Allergan	1963-12-31	2011-08-04
Herplex D	Liquid	.1 %	Topical	Allergan	1967-12-31	2011-08-04

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Sandoz Idoxuridine	Liquid	0.1 %	Topical	Sandoz Canada Incorporated	1999-02-15	2019-08-01

Chemical Identifiers

UNII: LGP81V5245
CAS number: 54-42-2
InChI Key: XQFRJNBWHJMXHO-RRKCRQDMSA-N
InChI: InChI=1S/C9H11IN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1
IUPAC Name: 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodo-1,2,3,4-tetrahydropyrimidine-2,4-dione
SMILES: OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(I)C(=O)NC1=O

References

Synthesis Reference

British Patent 1,024,156.

General References

Seth AK, Misra A, Umrigar D: Topical liposomal gel of idoxuridine for the treatment of herpes simplex: pharmaceutical and clinical implications. Pharm Dev Technol. 2004 Aug;9(3):277-89. [Article]
Otto SE: Radiopharmaceuticals (Strontium 89) and radiosensitizers (idoxuridine). J Intraven Nurs. 1998 Nov-Dec;21(6):335-7. [Article]
Fauth E, Zankl H: Comparison of spontaneous and idoxuridine-induced micronuclei by chromosome painting. Mutat Res. 1999 Apr 6;440(2):147-56. [Article]

External Links

Human Metabolome Database: HMDB0014394
KEGG Drug: D00342
PubChem Compound: 5905
PubChem Substance: 46507573
ChemSpider: 5694
BindingDB: 50370388
RxNav: 5653
ChEBI: 147675
ChEMBL: CHEMBL788
ZINC: ZINC000003834173
Therapeutic Targets Database: DAP000997
PharmGKB: PA164781019
PDBe Ligand: ID2
Drugs.com: Drugs.com Drug Page
Wikipedia: Idoxuridine

PDB Entries

1ki7

MSDS

Download (73.5 KB)

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count
2	Withdrawn	Treatment	Leukemias	1

Pharmacoeconomics

Manufacturers

Glaxosmithkline
Alcon laboratories inc
Allergan pharmaceutical

Packagers

Medisca Inc.

Dosage Forms

Form	Route	Strength
Solution / drops	Ophthalmic
Solution / drops	Ophthalmic	1 mg/1mL
Solution	Topical	5 g
Solution / drops	Ophthalmic	.1 %
Liquid	Topical	.1 %
Ointment	Ophthalmic
Cream	Topical
Solution	Topical
Liquid	Topical	0.1 %

Prices

Unit description	Cost	Unit
Idoxuridine powder	273.88USD	g

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	193	British Patent 1,024,156.
water solubility	2000 mg/L (at 25 °C)	MERCK INDEX (1996)
logP	-0.96	NARURKAR,MM & MITRA,AK (1988)

Predicted Properties

Property	Value	Source
Water Solubility	23.4 mg/mL	ALOGPS
logP	-0.7	ALOGPS
logP	-0.53	Chemaxon
logS	-1.2	ALOGPS
pKa (Strongest Acidic)	8.46	Chemaxon
pKa (Strongest Basic)	-3	Chemaxon
Physiological Charge	0	Chemaxon
Hydrogen Acceptor Count	5	Chemaxon
Hydrogen Donor Count	3	Chemaxon
Polar Surface Area	99.1 Å²	Chemaxon
Rotatable Bond Count	2	Chemaxon
Refractivity	64.4 m³·mol^-1	Chemaxon
Polarizability	26.17 Å³	Chemaxon
Number of Rings	2	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	No	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	+	0.8129
Blood Brain Barrier	+	0.6502
Caco-2 permeable	-	0.8707
P-glycoprotein substrate	Non-substrate	0.7139
P-glycoprotein inhibitor I	Non-inhibitor	0.8735
P-glycoprotein inhibitor II	Non-inhibitor	0.8719
Renal organic cation transporter	Non-inhibitor	0.8943
CYP450 2C9 substrate	Non-substrate	0.7834
CYP450 2D6 substrate	Non-substrate	0.8656
CYP450 3A4 substrate	Non-substrate	0.5445
CYP450 1A2 substrate	Non-inhibitor	0.9045
CYP450 2C9 inhibitor	Non-inhibitor	0.9108
CYP450 2D6 inhibitor	Non-inhibitor	0.9231
CYP450 2C19 inhibitor	Non-inhibitor	0.9093
CYP450 3A4 inhibitor	Non-inhibitor	0.8932
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.8505
Ames test	Non AMES toxic	0.9132
Carcinogenicity	Non-carcinogens	0.7699
Biodegradation	Not ready biodegradable	0.9542
Rat acute toxicity	2.0879 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9356
hERG inhibition (predictor II)	Non-inhibitor	0.8113

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	splash10-0006-9044000000-bccd33421cbd5827f9e3
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0udr-1059000000-4b46b60642243bb500dc
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-000b-9350000000-68b99f191a0e77b64ddd
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0ik9-0089000000-896e11a53b20023850d5
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-014r-1492000000-9376a1d1a379fc68d2c2
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-000l-4495000000-f9b6897b35a1a4c82e6f
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-000l-9740000000-13d0469495c5f4e9deed
Predicted 1H NMR Spectrum	1D NMR	Not Applicable
Predicted 13C NMR Spectrum	1D NMR	Not Applicable

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å²)	Source type	Source
[M-H]-	161.5749052	predicted	DarkChem Lite v0.1.0
[M-H]-	167.6111	predicted	DeepCCS 1.0 (2019)
[M+H]+	162.5263052	predicted	DarkChem Lite v0.1.0
[M+H]+	170.00667	predicted	DeepCCS 1.0 (2019)
[M+Na]+	162.3356052	predicted	DarkChem Lite v0.1.0
[M+Na]+	176.0048	predicted	DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Details1. DNA

Kind

Nucleotide

Organism

Humans

Pharmacological action

Yes

Actions

Other

DNA is the molecule of heredity, as it is responsible for the genetic propagation of most inherited traits. It is a polynucleic acid that carries genetic information on cell growth, division, and function. DNA consists of two long strands of nucleotides twisted into a double helix and held together by hydrogen bonds. The sequence of nucleotides determines hereditary characteristics. Each strand serves as the template for subsequent DNA replication and as a template for mRNA production, leading to protein synthesis via ribosomes.

References

Komissarova NV, Tiunova AA, Anokhin KV: Selective impairments to memory consolidation in chicks produced by 5'-iodo-2'-deoxyuridine. Neurosci Behav Physiol. 2010 Feb;40(2):215-23. doi: 10.1007/s11055-009-9237-0. Epub 2009 Dec 22. [Article]
Komissarova NV, Tiunova AA, Anokhin KV: [Selective disruption of memory consolidation in chicks produced by 5'-iodo-2'-deoxyuridine]. Zh Vyssh Nerv Deiat Im I P Pavlova. 2008 Nov-Dec;58(6):700-10. [Article]

Details2. Thymidine kinase

Kind: Protein
Organism: HHV-1
Pharmacological action: Unknown
Actions: Unknown

General Function: Thymidine kinase activity
Specific Function: In latent infection, may allow the virus to be reactivated and to grow in cells lacking a high concentration of phosphorylated nucleic acid precursors, such as nerve cells that do not replicate the...
Gene Name: TK
Uniprot ID: Q9QNF7
Uniprot Name: Thymidine kinase
Molecular Weight: 40896.475 Da

References

Wild K, Bohner T, Folkers G, Schulz GE: The structures of thymidine kinase from herpes simplex virus type 1 in complex with substrates and a substrate analogue. Protein Sci. 1997 Oct;6(10):2097-106. [Article]

Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:55

Idoxuridine

Identification

Structure for Idoxuridine (DB00249)

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Collision Cross Sections (CCS)

Targets

References

References